Justification and Approval for Sole Source TPOXX Requirement
Inactive
Contract Opportunity
Notice ID
JA-24-Edg-173
Department/Ind. Agency
DEPT OF DEFENSE
Sub-tier
DEPT OF THE ARMY
Major Command
AMC
Sub Command
ACC
Sub Command 2
ACC-CTRS
Sub Command 3
ACC-APG
Office
W6QK ACC-APG
Award Details
- Contract Award Date: Feb 15, 2024
- Contract Award Number: W911SR-22-C-0051
- Task/Delivery Order Number:
- Modification Number: P00004
- Contractor Awarded Unique Entity ID:
General Information
- Contract Opportunity Type: Justification (Original)
- Original Published Date: Feb 22, 2024 04:22 pm EST
- Inactive Policy: 30 days after published date
- Original Inactive Date: Mar 23, 2024
- Initiative:
- None
Classification
- Product Service Code: 6505 - DRUGS AND BIOLOGICALS
- NAICS Code:
- 325412 - Pharmaceutical Preparation Manufacturing
- Place of Performance: New York , NY 10065USA
Description
The purpose of this sole source within scope modification to Siga Technologies Inc., is to procure additional doses of TPOXX thereby replenishing existing National Stockpile quantities. TPOXX is an oral Smallpox Treatment in capsule form, approved by the United States Food and Drug Administration in 2018.
Attachments/Links
Contact Information
Contracting Office Address
- EDGEWOOD CONTRACTING DIV KO 8456 BRIGADE STREET
- ABERDEEN PROVING GROU , MD 21010-5424
- USA
Primary Point of Contact
- Scott Hoffman
- scott.i.hoffman2.civ@army.mil
- Phone Number +1 (520) 671-1470
Secondary Point of Contact
- Alexander Mayatte
- alexander.z.mayatte.civ@army.mil
- Phone Number +1 (520) 671-2930
History
- Mar 23, 2024 11:55 pm EDTJustification (Original)